AbbVie raises $9.5B in senior notes
What's the deal? AbbVieDealroom has a profile for this one. Try Dealroom → has entered into an underwriting agreement for a $9.5 billion multi-tranche senior notes offering in August 2026. The issue includes floating-rate and fixed-rate notes maturing from 2028 to 2066.
The structure. The offering comprises eight tranches, with coupons ranging from 4.00% to 6.00%. Morgan StanleyDealroom has a profile for this one. Try Dealroom →, BofA SecuritiesDealroom has a profile for this one. Try Dealroom →, J.P. Morgan and SG Americas SecuritiesDealroom has a profile for this one. Try Dealroom → served as joint book-running managers.
Use of proceeds. The prospectus supplement says proceeds may be used to refinance existing debt, fund acquisitions and support general corporate purposes. The offering is expected to be listed on the New York Stock Exchange.
Why it matters. The new debt will increase AbbVie's interest obligations and leverage while giving the pharmaceutical company long-dated financing capacity.
Read more: Minichart
Image credit: Alzheimer's Association Illinois Chapter
